In pharmacy news:

The FDA has approved Troxyca ER oxycodone-naltrexone extended-release (ER) capsules for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Troxyca has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes. It is the only oxycodone product with oral abuse-deterrent features described in the labeling.

Read more via Pain Medicine News here.

Leave a Comment

Your email address will not be published. Required fields are marked *